Avalo Therapeutics Inc stock is traded at $6.73, with a volume of 191,729. It is up +1.51% in the last 24 hours and down -50.48% over the past month. Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Previous Close:
$6.63
Open:
$6.90
24h Volume:
191,729
Relative Volume:
0.09
Market Cap:
$360.93M
Revenue:
$59,000
Net Income/Loss:
-$84.74M
P/E Ratio:
-
EPS:
-$5.82
Net Cash Flow:
-$59.69M
1W Performance:
-6.14%
1M Performance:
-50.48%
6M Performance:
-69.14%
1Y Performance:
-56.36%
1-Day Range:
$6.53$6.90
1-Week Range:
$6.53$7.63
52-Week Range:
$6.53$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
410-522-8707Address
1500 LIBERTY RIDGE DRIVE, WAYNE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS